MedAlliance Launches Origin SC and Origin NC PTCA Balloons in Europe

July 21, 2021—MedAlliance announced the launch of the semicompliant Origin SC and noncompliant Origin NC percutaneous transluminal coronary angioplasty (PTCA) balloons for vessel preparation in Europe and markets that recognize the CE Mark. MedAlliance noted that the devices complement the company’s Selution SLR sirolimus-eluting balloon for predilation.

According to the company, the Origin SC and Origin NC devices can be used to predilate a vessel before stent implantation or to postdilate a coronary stent to achieve accurate and controlled stent expansion. The balloons do not have to be used exclusively with Selution SLR.

The Origin SC PTCA balloon features a very low crossing profile for challenging lesions. The company offers the device in a broad portfolio of sizes, including 1-, 1.25-, 1.50-, and 1.75-mm balloon diameters to treat very small vessels and complex cases.

The Origin NC PTCA balloon combines high-pressure tolerance and controlled compliance with a crossing profile for challenging cases. The device’s minimal balloon longitudinal growth ensures focused dilatation force on the target lesion, which minimizes the risk of damaging healthy tissue. Origin NC features a low crossing profile and is particularly designed to treat tight stenoses in calcified, fibrotic lesions.

The Selution SLR was awarded European CE Mark approval for the treatment of coronary artery disease in May 2020 and is now available in Europe and all other countries where the CE Mark is recognized. It received CE Mark approval for the treatment of peripheral artery disease in February 2020.